Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COMy 2022 | The safety and efficacy of venetoclax plus carfilzomib and dexamethasone in patients with R/R MM

In this video, Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham, AL, shares some updates on the safety and efficacy of carfilzomib plus venetoclax and dexamethasone in patients with relapsed/refractory (R/R) multiple myeloma. Dr Costa first outlines the methodology used in this study, and further discusses some results, including the adverse event profile, tolerability, and activity of this combination. Following this, Dr Costa highlights the importance of finding effective treatment combinations for patients with t(11;14) and also mentions one of the limitations of this study. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.

Disclosures

Research support: Amgen, Janssen, BMS, AbbVie, Ionis, Genentech
Honorarium: Amgen, Janssen, Sanofi, Karyopharm, BMS, Astra Zeneca, Adaptive Biotechnologies, Takeda, Pfizer